Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

Inclusion Criteria: * Adult patients (≥18 years of age) * Histologically or cytologically confirmed NSCLC with liver metastases * Eligible for immune checkpoint inhibitors per treating medical oncologist * Disease must be measurable per RECIST criteria * ECOG Performance status of 0 - 2 * Adequate organ function per protocol. * Allowable prior therapy includes adjuvant durvalumab, prior radiotherapy outside the upper abdomen. * Patients must be willing and able to sign an informed consent form. * Participants of childbearing potential willing to undergo pregnancy test and use contraception per Appendix. Exclusion Criteria: * Liver tumor burden which cannot be targeted with SBRT per treating radiation oncologist * Presence of uncontrolled intercurrent illness or significant comorbidities precluding participation in a clinical study as determined by investigator * Diagnosis of underlying parenchymal end stage liver disease (cirrhosis) or biliary disease (primary biliary cirrhosis). * Other invasive malignancy active within 1 years, excluding in situ cancers * Presence of psychiatric or substance abuse disorders that would interfere with compliance or safety * Has a known history of active Bacillus Tuberculosis (TB), Hepatitis B or Hepatitis C infection * Has received a live (active) vaccine within 30 days of enrollment. * Active autoimmune disease that has required systemic treatment in the past 1 years aside from hormone replacement therapy (ie. thyroxine, insulin, or physiologic corticosteroid replacement therapy) * Baseline corticosteroid use (\>10 mg prednisone daily or equivalent) at study entry * Pregnancy or breast feeding